{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:13Z","timestamp":1789498933115,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/8\/5\/68\/Adhoc\/2020\/ECD-I"],"award-info":[{"award-number":["5\/8\/5\/68\/Adhoc\/2020\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SERB-CRG\/2019\/001483"],"award-info":[{"award-number":["SERB-CRG\/2019\/001483"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017009","name":"Institute of Nano Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bioadv.2023.213594","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:54:21Z","timestamp":1692618861000},"page":"213594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation"],"prefix":"10.1016","volume":"154","author":[{"given":"Krishna","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrim","family":"Jhilta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuraj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eupa","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neleesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioadv.2023.213594_bb0005","series-title":"Global Tuberculosis Report 2021: Supplementary Material","author":"W.H. Organization","year":"2022"},{"issue":"10181","key":"10.1016\/j.bioadv.2023.213594_bb0010","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioadv.2023.213594_bb0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2015.11.018","article-title":"Inhaled drug treatment for tuberculosis: past progress and future prospects","volume":"240","author":"Hickey","year":"2016","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bioadv.2023.213594_bb0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/ph16040581","article-title":"An insight into advances in developing nanotechnology based therapeutics, drug delivery, diagnostics and vaccines: multidimensional applications in tuberculosis disease management","volume":"16","author":"Chopra","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.bioadv.2023.213594_bb0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/pharmaceutics12121196","article-title":"Novel approaches for the treatment of pulmonary tuberculosis","volume":"12","author":"Tan","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.bioadv.2023.213594_bb0030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/thx.2003.019224","article-title":"Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection","volume":"59","author":"Breen","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.bioadv.2023.213594_bb0035","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.2147\/IDR.S211556","article-title":"Paradoxical reaction in the form of new pulmonary mass during anti-tuberculosis treatment: a case series and literature review","author":"Guo","year":"2019","journal-title":"Infect. Drug Resist."},{"issue":"2","key":"10.1016\/j.bioadv.2023.213594_bb0040","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1128\/AAC.01897-12","article-title":"Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice","volume":"57","author":"Verma","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bioadv.2023.213594_bb0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"Tyagi","year":"2015","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bioadv.2023.213594_bb0050","first-page":"1","article-title":"Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro: effect of tuberculosis drugs on clofazimine activity","volume":"6","author":"Zhang","year":"2017","journal-title":"Emerg. Microbes Infect."},{"issue":"3","key":"10.1016\/j.bioadv.2023.213594_bb0055","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J. Investig. Dermatol."},{"issue":"2","key":"10.1016\/j.bioadv.2023.213594_bb0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/scipharm89020019","article-title":"Clofazimine as a treatment for multidrug-resistant tuberculosis: a review","volume":"89","author":"Nugraha","year":"2021","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.bioadv.2023.213594_bb0065","series-title":"Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: Emergency Update 2008","author":"WHO","year":"2008"},{"issue":"6","key":"10.1016\/j.bioadv.2023.213594_bb0070","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.9b00276","article-title":"Solid-state behavior and solubilization of flash nanoprecipitated clofazimine particles during the dispersion and digestion of milk-based formulations","volume":"16","author":"Salim","year":"2019","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bioadv.2023.213594_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/45.1.77","article-title":"Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection","volume":"45","author":"Peters","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.bioadv.2023.213594_bb0080","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/cg301463z","article-title":"Clofazimine mesylate: a high solubility stable salt","volume":"12","author":"Bolla","year":"2012","journal-title":"Cryst. Growth Des."},{"issue":"6","key":"10.1016\/j.bioadv.2023.213594_bb0085","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/03639045.2014.971027","article-title":"Solubility and dissolution enhancement strategies: current understanding and recent trends","volume":"41","author":"Jain","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"26","key":"10.1016\/j.bioadv.2023.213594_bb0090","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.1007\/s10853-021-06205-5","article-title":"Systematic development and optimization of spray-dried quercetin-HP-\u03b2-cyclodextrin microparticles for DPI-based therapy of lung cancer","volume":"56","author":"Vaghasiya","year":"2021","journal-title":"J. Mater. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2023.213594_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral delivery of anticancer drugs: challenges and opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bioadv.2023.213594_bb0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.drudis.2018.01.016","article-title":"Pharmaceutical nanocrystals: production by wet milling and applications","volume":"23","author":"Malamatari","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bioadv.2023.213594_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2017.11.046","article-title":"Reclaiming hijacked phagosomes: hybrid nano-in-micro encapsulated MIAP peptide ensures host directed therapy by specifically augmenting phagosome-maturation and apoptosis in TB infected macrophage cells","volume":"536","author":"Sharma","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2023.213594_bb0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2018.12.076","article-title":"Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: a new paradigm of drug delivery for tuberculosis","volume":"558","author":"Sharma","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.bioadv.2023.213594_bb0115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1389203723666220526161109","article-title":"Taming the devil: antimicrobial peptides for safer TB therapeutics","volume":"23","author":"Jadhav","year":"2022","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bioadv.2023.213594_bb0120","series-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","first-page":"A17","article-title":"Hybrid nano-in-micro systems for lung delivery of Host Defence Peptides (HDP) as adjunct therapeutics for Pulmonary TB","author":"Sharma","year":"2018"},{"key":"10.1016\/j.bioadv.2023.213594_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.colsurfb.2015.12.017","article-title":"Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study","volume":"139","author":"Ruge","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"11","key":"10.1016\/j.bioadv.2023.213594_bb0130","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/jps.21380","article-title":"Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies","volume":"97","author":"Yang","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bioadv.2023.213594_bb0135","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/pharmaceutics14030538","article-title":"To enhance mucus penetration and lung absorption of drug by inhalable nanocrystals-in-microparticles","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bioadv.2023.213594_bb0140","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/03639045.2020.1821046","article-title":"Comparison of media milling and microfluidization methods for engineering of nanocrystals: a case study","volume":"46","author":"Chogale","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.bioadv.2023.213594_bb0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2018.03.007","article-title":"Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles: therapeutic effects in inflammatory and mechanistic murine models of osteoarthritis","volume":"276","author":"Maudens","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioadv.2023.213594_bb0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.powtec.2020.08.040","article-title":"Design and evaluation of inhalable nanocrystals embedded microparticles with enhanced redispersibility and bioavailability for breviscapine","volume":"377","author":"Chen","year":"2021","journal-title":"Powder Technol."},{"issue":"11","key":"10.1016\/j.bioadv.2023.213594_bb0155","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/acs.molpharmaceut.7b00690","article-title":"Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization","volume":"14","author":"Brunaugh","year":"2017","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.bioadv.2023.213594_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01803-z","article-title":"Autophagy-inducing inhalable co-crystal formulation of niclosamide-nicotinamide for lung cancer therapy","volume":"21","author":"Ray","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.bioadv.2023.213594_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112027","article-title":"Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-a for site-specific and controlled drug delivery for cancer therapy","volume":"123","author":"Vaghasiya","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"issue":"7","key":"10.1016\/j.bioadv.2023.213594_bb0170","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1021\/acsbiomaterials.0c00823","article-title":"Targeted pulmonary delivery of the green tea polyphenol epigallocatechin Gallate controls the growth of mycobacterium tuberculosis by enhancing the autophagy and suppressing bacterial burden","volume":"6","author":"Sharma","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.bioadv.2023.213594_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122585","article-title":"Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials","author":"Jakhar","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioadv.2023.213594_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121097","article-title":"Antimicrobial activity of synthetic antimicrobial peptides loaded in poly-\u0190-caprolactone nanoparticles against mycobacteria and their functional synergy with rifampicin","volume":"608","author":"Sharma","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.bioadv.2023.213594_bb0185","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am. J. Respir. Crit."},{"issue":"1","key":"10.1016\/j.bioadv.2023.213594_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19412-6","article-title":"Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis","volume":"11","author":"Moreira-Teixeira","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bioadv.2023.213594_bb0195","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/pharmaceutics13111825","article-title":"Inhalable microparticles embedding calcium phosphate nanoparticles for heart targeting: the formulation experimental design","volume":"13","author":"Quarta","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2023.213594_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106158","article-title":"Particle engineering in dry powders for inhalation","volume":"172","author":"Scherlie\u00df","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioadv.2023.213594_bb0205","first-page":"1","article-title":"Nanocrystals: characterization overview, applications in drug delivery, and their toxicity concerns","author":"Jahangir","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.bioadv.2023.213594_bb0210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2022.03.012","article-title":"Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes","volume":"345","author":"McGuckin","year":"2022","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bioadv.2023.213594_bb0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/pharmaceutics12060523","article-title":"Development of a self-emulsifying drug delivery system for optimized topical delivery of Clofazimine","volume":"12","author":"van Staden","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioadv.2023.213594_bb0220","series-title":"Nanotechnology Based Approaches for Tuberculosis Treatment","first-page":"91","article-title":"Inhalable polymeric dry powders for antituberculosis drug delivery","author":"Adlakha","year":"2020"},{"key":"10.1016\/j.bioadv.2023.213594_bb0225","article-title":"Nanotherapeutics for pulmonary drug delivery: an emerging approach to overcome respiratory diseases","volume":"81","author":"Kole","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bioadv.2023.213594_bb0230","series-title":"ISO\u201310993-5 Biological Evaluation of Medical Devices-Part 5: Tests for In Vitro Cytotoxicity","author":"I.S. Organization\u2013ISO","year":"2009"},{"issue":"4","key":"10.1016\/j.bioadv.2023.213594_bb0235","first-page":"1083","article-title":"Chemotherapeutic activity of clofazimine and its analogues against mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies","volume":"151","author":"Jagannath","year":"1995","journal-title":"Am. J. Respir. Crit."},{"issue":"6","key":"10.1016\/j.bioadv.2023.213594_bb0240","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/jac\/dkx022","article-title":"Susceptibilities of MDR mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic\/pharmacodynamic parameters","volume":"72","author":"Cavanaugh","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.bioadv.2023.213594_bb0245","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bioadv.2023.213594_bb0250","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"9","key":"10.1016\/j.bioadv.2023.213594_bb0255","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00186-22","article-title":"Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB\/c mice with chronic mycobacterium tuberculosis infection","volume":"66","author":"Brunaugh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioadv.2023.213594_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.actbio.2015.08.005","article-title":"Investigating the role of Pluronic-g-cationic polyelectrolyte as functional stabilizer for nanocrystals: impact on paclitaxel oral bioavailability and tumor growth","volume":"26","author":"Sharma","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioadv.2023.213594_bb0265","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.colsurfb.2015.12.017","article-title":"Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study","volume":"139","author":"Ruge","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.bioadv.2023.213594_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2020.05.013","article-title":"Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis","volume":"324","author":"Sharma","year":"2020","journal-title":"J. Control. Release"}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950823003175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950823003175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:53:04Z","timestamp":1757425984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950823003175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":54,"alternative-id":["S2772950823003175"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2023.213594","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2023.213594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"213594"}}